Literature DB >> 8323545

A novel [99m]technetium-labeled nitroheterocycle capable of identification of hypoxia in heart.

W L Rumsey1, J E Cyr, N Raju, R K Narra.   

Abstract

A novel [99m]technetium-labeled nitroimidazole was preferentially taken up and retained by hypoxic cardiac muscle. In rat hearts perfused with O2 or N2 equilibrated cell-free medium, uptake of the infused nitroheterocycle and its subsequent washout displayed biphasic kinetics. For both uptake and washout, the early phase was very rapid whereas the late phase was much slower. The amount of radioactivity retained after 40 min of clearance was about two-fold greater in hypoxic hearts than in normoxic hearts. Cardiac myocytes and mitochondria isolated from rat heart also accumulated the nitroheterocycle. Association of the compound with heart cells was inversely related to the level of available oxygen and was independent of intracellular energy level or mitochondrial redox state in the presence of oxygen. The results indicate that this [99mTc]labeled nitroimidazole may serve as a sensitive marker of hypoxic myocardium.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8323545     DOI: 10.1006/bbrc.1993.1758

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Effects of low flow and hypoxia on myocardial retention of technetium-99m BMS181321.

Authors:  R D Okada; K N Nguyen; H W Strauss; G Johnson
Journal:  Eur J Nucl Med       Date:  1996-04

2.  HL-91-technetium-99m: a new marker of viability in ischemic myocardium.

Authors:  R D Okada; G Johnson; K N Nguyen; L R Carlson; D Beju
Journal:  J Nucl Cardiol       Date:  1999 May-Jun       Impact factor: 5.952

Review 3.  Nitroimidazoles and imaging hypoxia.

Authors:  A Nunn; K Linder; H W Strauss
Journal:  Eur J Nucl Med       Date:  1995-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.